Podcasts about The BMJ

Broadcast from KSQD, Santa Cruz on 2-26-2026: Dr. Dawn opens with an urgent measles advisory, noting the virus has an R-value of 15 compared to COVID's peak of 5, with South Carolina reporting over 1,000 cases. She recommends those who received only one MMR shot—particularly people now in their 60s—get an immune titer blood test, as protection declines after 40-50 years. Measles can cause "immune amnesia" destroying immunity to other pathogens, and rarely leads to fatal subacute sclerosing panencephalitis years later. Dr. Dawn criticizes Quest Labs' cholesterol reporting, which flags average levels as "moderate risk" with alarming red H markers even when values fall within their own stated normal ranges. She explains this creates unnecessary panic and pushes patients toward statins based on outdated 2008-2012 guidelines, when cardiology has since recognized that cholesterol can be too low. An emailer asks how an EKG can detect a past heart attack from "jagged lines." Dr. Dawn explains that each spike represents electrical signals moving toward or away from electrode pads, and a 12-lead EKG views the heart from multiple angles—smaller-than-expected spikes in specific leads indicate dead or damaged heart muscle. She urges everyone to learn CPR and AED use, which more than doubles survival chances. An emailer reports that food tastes strong on the first bite but becomes tasteless thereafter. Dr. Dawn identifies numerous medications causing taste changes including calcium channel blockers, beta blockers, statins, diuretics, and even acetaminophen. She also highlights zinc—both deficiency and toxicity above 40mg daily can impair taste, noting a zinc nasal spray was pulled from market after causing smell loss. An emailer asks about Prenuvo full-body MRI scans costing $499-1,000. Dr. Dawn cautions that while Prenuvo found 22 cancers in 1,000 people scanned, 1 in 20 scans requires follow-up biopsy and more than half are false positives—leading to stress, expense, and potential complications from unnecessary procedures. An emailer asks about seed oils after reading a Johns Hopkins article defending them. Dr. Dawn distinguishes fruit oils (olive, avocado) from industrially-extracted seed oils requiring hexane solvent, a neurotoxin that may leave residues despite claims of evaporation. She cites a BMJ study showing coconut oil raised HDL (good cholesterol) while matching olive oil's LDL impact, and recommends cold-pressed oils while avoiding hexane-extracted products, especially for infants.

Are men wimps or just immunologically inferior? Chris and Sophie review the evidence to decide if respiratory viruses really do hit men harder or if they are just looking for attention. Also Chris gushes about his favorite TV show, “All Creatures Great and Small.”    Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References: 1) Sophie's article: 2) BMJ review:  https://www.bmj.com/content/359/bmj.j5560 3) Man flu is not a thing post-hoc analysis: https://www.sciencedirect.com/science/article/pii/S0022399922003324#bbb0155

Those working in clinical trials will recall that in 2025 updates were published for the SPIRIT standard clinical trial protocol items and the CONSORT guideline for reporting randomised clinical trials. The Lancet Child & Adolescent Health will be co-publishing the first child and adolescent extensions to the SPIRIT and CONSORT reporting guidelines, along with the BMJ and JAMA Paediatrics. In this conversation with the SPIRIT and CONSORT child and adolescent project leads, Ami Baba and Martin Offringa, we discuss the need for child and adolescent specific reporting standards, the importance and value of engaging caregivers and young people in the process of developing the standards, and the potential for the SPIRIT-C and CONSORT-C reporting standards to positively impact the quality and inclusivity of paediatric clinical trials across all disciplines caring for neonates, infants, children, and adolescents.Click here to read the full articles:CONSORT-C https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00004-0/fulltextSPIRIT-C https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00005-2/fulltextSend us your feedback!Read all of our content at https://www.thelancet.com/?dgcid=buzzsprout_tlv_podcast_generic_lancetCheck out all the podcasts from The Lancet Group:https://www.thelancet.com/multimedia/podcasts?dgcid=buzzsprout_tlv_podcast_generic_lancetContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this week's episode, we challenge long-held medical narratives, starting with how the healthcare system manages life after a cancer diagnosis. While medical advancements mean more people are surviving cancer than ever before, many patients report a "cliff-edge" experience where coordinated care effectively vanishes once primary treatment ends. We are joined by Dr. Rosalind Adam, an Academic GP at the University of Aberdeen, who argues that it is time to stop viewing cancer as a discrete, one-off episode and instead integrate it into routine chronic disease management.  Next, we dive into a landmark study from Sweden that is overturning the conventional notion of autism as a predominantly male condition. Historically, autism has been cited as having a 4:1 male-to-female ratio, but new data suggests this gap may be a byproduct of timing rather than biology. We speak with Dr. Caroline Fyfe, a medical epidemiologist at the University of Edinburgh, and Dr. Natasha Marrus, a child psychiatrist at Washington University in St. Louis. They discuss their analysis of 2.7 million individuals, which revealed a significant female catch-up during adolescence, showing that by age 20, the diagnosis ratio approaches 1:1. The team explores why girls are so often missed in childhood and what this shift means for the future of sex-sensitive diagnostic practices. Reading List For more details on the research discussed in this episode, you can access the full papers on bmj.com: Cancer is a chronic disease: why don't we treat it as one? Adam R, Hogg DR, Ritchie LD, Nekhlyudov L. BMJ 2026;392:e086624. Time trends in the male to female ratio for autism incidence: population based, prospectively collected, birth cohort study. Fyfe C, et al. BMJ 2026;392:e084164. Please subscribe to the Medicine & Science podcast on your favourite platform to get the latest episodes. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts, Spotify, or YouTube.

According to research published in The BMJ in 2002, around 40% of people experience some age-associated memory impairment after reaching 65. Thankfully only 1% of those affected will then go on to have dementia each year. But still, it's important to be aware of how effective your memory is, whatever your age. An impairment can be a sign of cognitive decline, which becomes more likely the older we get. How does our memory actually work? What happens when we have a memory lapse then? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: ⁠⁠Can you really lose weight by walking?⁠⁠ ⁠⁠Can you improve your relationship by learning your love language?⁠⁠ ⁠⁠Are you spending more on groceries due to stretchflation?⁠⁠ A podcast written and realised by Joseph Chance. First Broadcast: 11/9/2024 Learn more about your ad choices. Visit megaphone.fm/adchoices

Un nouvel épisode du Pharmascope est disponible! Dans ce 172e épisode, Nicolas, Olivier et Amélie discutent d'un problème très commun… L’hypothyroïdie! Cette première partie est consacrée à l'évaluation, le diagnostic et la prise en charge de l’hypothyroïdie.  Les objectifs pour cet épisode sont les suivants: Discuter de l'évaluation et du diagnostic de l’hypothyroïdie Discuter des de la prise en charge et des différents traitements de l'hypothyroidie Discuter des caractéristiques pharmacologiques de la lévothyroxine Ressources pertinentes en lien avec l'épisode Jonklaas J, et coll; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751. Chaker L, et coll. Hypothyroidism. Nat Rev Dis Primers. 2022 May 19;8(1):30. doi: 10.1038/s41572-022-00357-7. Wilson SA, Stem LA, Bruehlman RD. Hypothyroidism: Diagnosis and Treatment. Am Fam Physician. 2021 May 15;103(10):605-613. Chaker L, Papaleontiou M. Hypothyroidism: A Review. JAMA. 2025 Sep 3. Hollowell JG, et coll. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002 Feb;87(2):489-99. McCormack JP, Holmes DT. Your results may vary: the imprecision of medical measurements. BMJ. 2020 Feb 20;368:m149. Pollock MA, et coll. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ. 2001 Oct 20;323(7318):891-5. Chen Y, Tai HY. Levothyroxine in the treatment of overt or subclinical hypothyroidism: a systematic review and meta-analysis. Endocr J. 2020 Jul 28;67(7):719-732. Roos A, et coll. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch Intern Med. 2005 Aug 8-22;165(15):1714-20. da Rocha BS, et coll. Effects of timing and scheduling in levothyroxine adherence to hypothyroidism control: Meta-analysis with trial sequential analysis of Randomized Clinical Trials. Endocrine. 2025 Jul;89(1):52-61.

Dr Remle Crowe returns to the podcast to discuss three new papers with Dr Jarvis: Two papers on epinephrine in cardiact arrest (including one on trauma!) and one on pulse oximetry in hypoxemic patients with darker skin. We might nerd out a bit on methodology, tacos, and have a few book recommendations.Citations: Martin DS, Doidge JC, Gould D, et al.: The impact of skin tone on performance of pulse oximeters used by NHS England COVID Oximetry @home scheme: measurement and diagnostic accuracy study. BMJ. 2026;January 14;392Witt CE, Shatz DV, Robinson BRH, et al.: Epinephrine in Prehospital Traumatic Cardiac Arrest—Life Saving or False Hope? Prehospital Emergency Care. 2026;January 2;30(1):153–61.Lilien EJ, Ashburn NP, George TS, et al.: Single Dose Epinephrine Protocol Is Associated With Improved Survival of Older Adults With Out‐Of‐Hospital Cardiac Arrest. Academic Emergency Medicine. 2025Perez CP: Invisible Women: Data Bias in a World Designed for Men. New York, NY, Abrams Press, 2019.O'Neil C: Weapons of Math Destruction: How Big Data Increases Inequality and Threatens Democracy. New York, NY, Crown Publishing Group, 2017. • 6. Perkins GD, Ji C, Deakin CD, et al.: A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2018;August 23;379(8):711–21.

FONTES COMPLETAS - EPISÓDIO PODCAST

The management of complex regional pain syndrome (CRPS) continues to challenge clinicians—especially when conservative and interventional strategies fall short. This episode of RAPM Focus, hosted by RAPM Editor and Social Media Editor Ryan D'Souza, MD, explores these challenges in managing CRPS with Daniël van der Spek, MD, and Frank Huygen, MD, PhD, FIPP, FFPMCAI, following the August 2025 publication of their original research paper, “Long-term outcomes of amputation in patients with complex regional pain syndrome (CRPS): a mixed-methods study.” In rare and severe cases, amputation has been proposed as a last resort intervention, but the topic remains completely controversial. How does one weigh the potential relief of unrelenting pain against the risk of further complications and disability from an amputation? This episode explores a fascinating, mixed-method study into the long-term outcomes of patients with CPRS undergoing limb amputation in hopes of pain relief, despite risks of residual pain or phantom limb pain. Dr. Daniël van der Spek is a medical doctor and PhD candidate at the Erasmus University Medical Center under the supervision of Professor Huygen his research focus is on CPRS with a particular emphasis on interventional pain management. Dr. Frank Huygen is an anesthesiologist and pain physician serving as the head of the Department of Pain Medicine at Erasmus University Medical Center, and has been a full professor since 2009. His expertise focuses on CPRS and neuromodulation. He leads multiple national and international research projects, and maintains close collaborations with CRPS patient organizations, in both the Netherlands and the United States. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on X @RAPMOnline, LinkedIn @Regional Anesthesia & Pain Medicine, Facebook @Regional Anesthesia & Pain Medicine, and Instagram @RAPM_Online.

There has been a shift in cervical cancer screening from primary cytology based to HPV based. Even HPV screening has had its evolution from physician collected samples to patient self-collection, either in a clinical setting or at home with an approved collection system. In May 2025, the FDA cleared the first at-home self-collection kit for HPV screening, specifically the Teal Wand by Teal Health. Now, we are seeing the advent of POSSIBLY another avenue for cervical HPV testing- although it is a bit awkward: the use of menstrual blood as an HPV screening test. In this episode we will review a new cross-sectional, population-based study from China which compared testing menstrual blood for human papillomavirus during cervical cancer screening to clinician-collected cervical samples for human papillomavirus (HPV). This concept, and these results, are not new at all! And there are important limitations to consider at this time. Listen in for details.1. Testing menstrual blood for human papillomavirus during cervical cancer screening in China: cross sectional population based study. BMJ 2026; 392 doi: https://doi.org/10.1136/bmj-2025-084831 (Published 04 February 2026)BMJ 2026;392:e084831https://www.bmj.com/content/392/bmj-2025-0848312. Naseri S, Young S, Cruz G, Blumenthal PD. Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood. Obstet Gynecol. 2022 Sep 1;140(3):470-476. doi: 10.1097/AOG.0000000000004904. Epub 2022 Aug 3. PMID: 35926207; PMCID: PMC9377370.3. Fokom Domgue J, Chandra M, Oladoyin O, Desai M, Yu R, Shete S. Women's Preferences for Home-Based Self-Sampling or Clinic-Based Testing for Cervical Cancer Screening. JAMA Netw Open. 2026;9(2):e2558841. doi:10.1001/jamanetworkopen.2025.58841

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest on Ozempic from medical breakthroughs to real-life health impacts.Recent research from the University of Cambridge highlights a key nutrition risk with Ozempic and Wegovy. These drugs slash calorie intake by sixteen to thirty-nine percent by mimicking glucagon-like peptide-one, curbing appetite and boosting fullness. But without proper guidance, users risk muscle loss up to forty percent of total weight shed and deficiencies in protein, vitamins, and minerals, leading to fatigue, hair loss, or weakened immunity. Experts like Doctor Marie Spreckley urge structured nutrition support, drawing from bariatric surgery principles: prioritize nutrient-dense foods and high-quality protein spread across meals. Doctor Adrian Brown from University College London notes most users, about ninety-five percent in the United Kingdom, get these privately without follow-up, unlike National Health Service programs pairing them with diet and exercise.Sex differences are emerging too. A study in PubMed Central reports glucagon-like peptide-one receptor agonist use surged from twenty nineteen to twenty twenty-two, especially among women, where obesity links strongly to prescriptions and yields greater weight loss, like fifteen point three kilograms in semaglutide trials.Looking ahead per GoodRx projections for twenty twenty-six, Ozempic is under Food and Drug Administration review for peripheral artery disease, improving walking in diabetes patients, and heart failure with preserved ejection fraction. Higher Wegovy doses up to seven point two milligrams could hit nearly twenty-one percent weight loss. Exciting combos like CagriSema show twenty-three percent loss in trials, outpacing rivals. Oral options expand too: Wegovy pills launched this year, and orforglipron may approve mid-year, easing access without needles.The Food and Drug Administration warns against unapproved versions mimicking semaglutide, sold illegally online. Experts from George Mason University, like Martin Binks and Raedeh Basiri, stress holistic care: pair drugs with dietitians, exercise, and mental support to avoid regain, as a twenty twenty-six BMJ review notes two-thirds weight return within a year off meds.Ozempic transforms lives but thrives with lifestyle integration for lasting health.Thanks for tuning in, listeners. Subscribe for more updates. This has been a Quiet Please production. For more, check out Quiet Please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Salut les sportifs intelligents ! Cette semaine on va parler de ces mensonges qui te font perdre du temps, de l'énergie et qui freinent tes résultats. Tu en as marre des conseils contradictoires ? Entre la peur du cholestérol, l'obsession du cardio à jeun et les vendeurs de thé détox, il est difficile de démêler le vrai du faux. Dans cet épisode "coup de poing", je sors la science pour DÉTRUIRE 7 mythes tenaces qui circulent encore dans les salles de sport et sur les réseaux sociaux. Au programme de ce debunking :

The Study Cardiology Willfully Ignored for Over Two Decades Written by Sayer Ji on January 27, 2026. Posted in Current News' https://principia-scientific.com/the-study-cardiology-willfully-ignored-for-over-two-decades/     Authored by Lois Lamerato et al. from Henry Ford Health System study by Lois Lamerato et al  of data from Michigan's integrated healthcare system in Michigan to compare chronic health outcomes in vaccinated versus unvaccinated children. Vaccination exposure was defined as receiving at least one vaccine Vaccinated children had a 2.5 higher adjusted hazard ratio for any chronic condition Specific increcases include asthma, autoimmune disease, atopic disease, eczema, and neurodevelopmental disorders. The 10-year probability of being free from chronic conditions was 83% in unvaccinated vs. 43% in vaccinated. No conditions were higher in unvaccinated.   Study by AR Mawson et al – J Translational Science Survey-based study compared homeschooling children who were vaccinated versus unvaccinated. Higher rates of neurodevelopmental disorders, asthma, and allergies among vaccinated children Vaccinated children had fewer vaccine-preventable infections.   Study by BS Hooker et al – SAGE Open Medicine Retrospective analysis of health outcomes between vaccinated and unvaccinated children. Higher rates of asthma, developmental delays and ear infections in vaccinated children.   Study by NZ Miller – J Translational Science A follow-up analysis to adjust for additional covariates such as breastfeeding and cesarean birth. Reported increased odds of certain chronic conditions among vaccinated children. This is not very convincing study if I am to be honest   Study by AR Mawson & BS Hooker – Frontiers of Public Health Analyzed pediatric billing data and reported increased office visits and diagnoses among vaccinated children. Reported igher rates of neurodevelopmental disorders, asthma, and allergies in vaccinated children However, the journal retracted this article on the grounds it did not disclose conflicts of interest   University of Hong Kong -- This one I know from memory – don't know the journal Double blind placebo study comparing flu vaccinated vesus saline placebo vaccinated Followed for 9 months Vaccinated – almost 4-fold increase in getting other non-flu respiratory infections compared to unvaccinated Only slight increase in flu cases among unvaccinated compared to vaccinated   DeStefano et al -- J Translational Neurdegeneration Study analyzed children in metropolitan Atlanta to examine a link between the age of first MMR vaccine receipt and autism diagnosis. Reports that earlier MMR vaccination increased autism risk in specific subgroups, compared to to later-vaccinated children.   J Lyons-Weiler – Intl J Environmental Research and Public Health Unvaccinated children reportedly had fewer chronic illnesses but more vaccine-preventable infections.   Roma Schmitz et al -  Deutsch Arztebl Intl (German journal) – early study in 2011 Large survey to assess whether vaccination status affects infectious and atopic diseases. Unvaccinated had higher vaccine-preventable diseases (e.g., pertussis, measles) but lower atopic diseases There were fewer median infections in unvaccinated young   P Aaby et al – series of studies between 1995-2016 – BMJ, Vaccine, J Tropical Medicine Some vaccines (especially DTP) associated with higher all cause mortality in low income settings compared to those who did not receive DTP  

In this episode of The Consummate Athlete Podcast, Peter and Molly discuss a recent study performed by researchers at Harvard T.H. Chan School of Public Health that associates the variety of movement done with a reduced risk of premature death, even at lower volumes of exercise.  Implications for athletes and for play! How varied strength training might help The 4'cs for Consummate Athlete Adding more variety to indoor trainer workouts  Thinking beyond organized sport to movements 

You've probably heard of GLP-1 drugs like semaglutide and tirzepatide—and maybe you've even wondered, “Should I be on one of these?” This conversation is my honest, compassionate take on these powerful weight loss medications: not medical advice, not fear-mongering, and definitely not hype.In this episode, I unpack what GLP-1 receptor agonists (a class of anorectic drugs) really are, how they work, why they're so effective for fat loss—and what most people don't realize about what happens when you stop taking them. I'll walk through recent research, potential side effects, and the rebound weight gain that happens to so many… not because you failed, but because of basic human physiology.This is a supportive conversation for anyone who's considering these medications, already using them, or just wants to better understand their role in the weight loss space. And while there's no shame in using tools like these, lifestyle change still has to be the foundation. Always.What we go over:What GLP-1 drugs actually do in your bodyWhat happens after you stop taking them (and why)Why muscle loss and metabolic slowdown are often overlookedThe importance of strength training, protein, and movement—even with medsWhy long-term success still comes down to habits, not just prescriptionsHow to think critically and compassionately about weight loss toolsThese drugs are effective—but they're not magic. Let's have the real conversation.Sources:Quarenghi M, Capelli S, Galligani G, Giana A, Preatoni G, Turri Quarenghi R. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. Journal of Clinical Medicine. 2025; 14(11):3791. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized StudiesSun Q. (2026). Weight regain after cessation of GLP-1 drugs. BMJ (Clinical research ed.), 392, r2586. https://doi.org/10.1136/bmj.r2586West S, Scragg J, Aveyard P, Oke J L, Willis L, Haffner S J P et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis BMJ 2026; 392 :e085304 doi:10.1136/bmj-2025-085304Support the showGet Weekly Health Tips: thrivehealthcoachllc.com Join the Thrive Collective Facebook group Let's Connect:@‌ashleythrivehealthcoach or via email: ashley@thrivehealthcoachingllc.com Podcast Produced by Virtually You!

Après un parcours initial de physique à supoptique, Clément Apélian fait un 180° et obtient un doctorat en sciences cognitives sur l'hypnose. Aujourd'hui, il est le directeur de recherche du laboratoire PRHySME, spécialisé en l'étude phénoménologique de l'hypnose. Dans cet épisode, vous allez explorer la vérité derrière un sujet qui nous touche tous, mais que l'on ne comprends pas complètement : le placebo. Est-ce que vous savez réellement ce que c'est et comment il fonctionne ? Découvrez-le en écoutant l'épisode. Retrouvez Clément :- Laboratoire PRHySME : https://www.prhysme.com/- Sa page LinkedIn : https://www.linkedin.com/in/cl%C3%A9ment-apelian-9a0785b2/?originalSubdomain=frRéférences : - Extrait Jérémy Ferrari sur l'homéopathie : https://www.youtube.com/watch?v=AUjBT6xHcdE- Autour de 50% des médecins prescrive des placebo une fois par mois ou plus. (Nitzan & Lichtenberg 2004 BMJ ; Sherman & Hickner 2008 Journal of general internal medicine)- Invention de l'homéopathie en 1806 Test 1834 (Trousseau and Gouraud 1834 Expériences homéopathiques tentées à l'Hôtel-Dieu de Paris)- Electrosensibles incapable de faire mieux que les non-électrosensibles et que le hasard sur 182 électrosensibles (Martin Röösli 2008 Environmental Research)- Cas d'hospitalisation suite à la prise d'un placebo : Reeves et al. (2007) General Hospital Psychiatry- Placebo dépend de l'interaction (taille d'effet : 0.85-1.45 étudié directement contre 0.15 quand il est utilisé comme contrôle) Vase et al. 2002 Pain  / et de l'invasivité Schenk et al. 2024 Brain (spray nasal) – Meissner and Linde (2018) Are Blue Pills Better Than Green? How Treatment Features Modulate Placebo Effects (International review of neurobiology)- Open label placebo (von Wernsdorff et al. 2021 Scientific Reports) fonctionne mais encore peu étudiéL'art du mentaliste, un podcast animé par Taha Mansour et Alexis Dieux, musique par Antoine Piolé.Retrouvez Taha Mansour :- Son site : www.tahamansour.com- Instagram / Facebook : @TahaMentalismeRetrouvez Alexis Dieux :- Son site : https://www.alexisdieux.com/- Instagram : @alexisdieuxhypnose

Oprah Winfrey shared striking insights this week on her experience with Ozempic, a popular drug known as semaglutide for type two diabetes and weight management. On the Today Show on January 21, 2026, the media icon revealed she gained 20 pounds after stopping the medication for nearly a year. She wanted to prove she could maintain her weight through discipline alone, including hiking regularly and exercising up to two hours a day, six days a week. But the weight returned quickly, leading her to resume the injections. Oprah compared it to lifelong blood pressure medicine, saying she has proven to herself that she needs it. A new BMJ study mentioned in the discussion found that people quitting GLP-one drugs like Ozempic regain about four kilograms every month and can recover all lost weight within two years.This personal story aligns with warnings from experts this week. Doctor Andre Teixeira, a bariatric surgeon, told Scripps News that without lifestyle changes, most people regain 67 percent of their weight within two years after stopping these drugs. The medications slow digestion and reduce cravings, but effects fade 30 to 90 days after discontinuation, often worsening prior metabolic issues. Gina Leinninger, a physiology professor at Michigan State University, called them forever drugs in an MSUToday article, noting the body fights to defend higher weights once gained, making sustained loss challenging even with diet and exercise.Meanwhile, legal concerns mount over Ozempic side effects. Lawsuit Information Center reported on January 17, 2026, that Novo Nordisk faces potential mass torts in New Jersey for claims of gastroparesis, or stomach paralysis, and NAION, a vision loss condition. The GLP-one multidistrict litigation now includes over 3,000 cases, with predictions of high value for severe NAION injuries. Gastric emptying studies are key to proving these claims, as symptoms like nausea, vomiting, and bloating can persist without cure.These developments highlight Ozempic's dual role as a powerful weight loss tool and a medication demanding long-term commitment amid emerging risks.Thanks for tuning in, listeners. Please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

​‪@RichardJMurphy‬, political economist and tax campaigner, joins Kamran Abbasi, Editor in Chief of The BMJ. In the UK an ongoing dispute between resident doctors and the Labour Government saw doctors go on strike in mid-December. With Winter pressure piling on and cost-of-living on the rise, do doctors have a credible case of pay rises? And more broadly, how can the economic situation of the NHS be improved? 00:00 Introduction 01:30 Doctor Pay Claims 04:33 Inflation Measures 07:29 Affordability Crisis 09:48 Market Forces Arguments 12:52 NHS Affordability 15:00 Youth Unemployment 19:14 Political Priorities 23:10 Neoliberal Capitalism 27:35 Mixed Economy Alternative 32:32 Prescription for NHS

Lorsque l'on parle de « brûler » des graisses, l'image qui nous vient souvent en tête est celle d'un glaçon qui fond. En réalité, la biologie raconte une histoire bien plus surprenante : lorsque nous perdons de la graisse après un effort physique, la majorité de cette graisse quitte notre corps… par la respiration.Tout commence dans nos cellules. Lorsqu'elles ont besoin d'énergie — pendant une séance de sport, une marche rapide ou même une simple montée d'escaliers — elles vont puiser dans leurs réserves : les triglycérides. Ces molécules sont stockées dans les adipocytes, nos cellules graisseuses. Leur rôle est d'emmagasiner de l'énergie sous une forme compacte et stable, en attendant un moment de besoin. Quand l'organisme réclame du carburant, ces triglycérides sont démontés en acides gras et en glycérol.C'est dans les mitochondries que la véritable « combustion » a lieu. Grâce à l'oxygène que nous respirons, ces acides gras sont métabolisés. Et c'est là que survient la révélation : la graisse ne disparaît pas, elle se transforme. Son produit final n'est pas de la chaleur ni de la sueur, mais principalement du dioxyde de carbone (CO₂) et de l'eau.Pour donner une idée concrète : si vous perdez 100 g de graisse, environ 84 g seront transformés en CO₂. À un rythme respiratoire normal, cela représente plusieurs dizaines de litres de CO₂ expirés au fil des heures. La dépense énergétique d'une séance de sport d'intensité modérée peut mobiliser 50 à 150 g de graisse, ce qui signifie que l'on expire littéralement des dizaines de grammes de graisse sous forme de CO₂ après un seul entraînement.Les 16 % restants de la masse initiale sont transformés en eau, éliminée par la sueur, l'urine et même la vapeur d'eau expirée. Contrairement aux idées reçues, la transpiration n'est pas la preuve que nous « brûlons » de la graisse : elle sert surtout à refroidir le corps.Cette découverte — popularisée après une étude publiée en 2014 dans BMJ — a renversé nombre d'idées que l'on croyait acquises : maigrir est avant tout un processus respiratoire. Chaque mouvement accélère la transformation des triglycérides en CO₂, et c'est en expirant que nous perdons réellement du poids.En résumé : pour perdre de la graisse, il faut bouger… et respirer. L'oxygène que nous inspirons, et surtout le CO₂ que nous expirons, portent la signature chimique de notre perte de poids. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Firearm ownership has surged in the U.S., yet safety discussions remain uncommon in clinical care. An NEJM article supports routine, nonpolitical firearm counseling using the “3 A's” (Ask, Advise, Assist) to reduce risks such as suicide and unintentional injury. Separately, a BMJ meta-analysis shows that patients stopping GLP-1 weight-loss medications typically regain weight within 1.5–2 years, reinforcing obesity as a chronic condition requiring long-term planning. Finally, a large sham-controlled trial found no meaningful benefit of trigeminal nerve stimulation for pediatric ADHD, suggesting prior perceived effects were placebo-driven.

Kick off 2026 with the January episode of RAPM Focus, where RAPM Social Media Editor Alopi Patel, MD, converses with Josh Gleicher, MD, MSc, FRCPC, and Hermann dos Santos Fernandes, MD, PhD, following the September 2025 publication of their original research paper, “Outpatient continuous adductor canal block (CACB) for total knee arthroplasty: a double-blinded randomized placebo-controlled trial.” Dr. Gleicher is a staff anesthesiologist and regional anesthesia expert at Mount Sinai Hospital in Toronto, Canada. He completed his anesthesiology training and fellowship in regional anesthesia at the University of Toronto and holds a master's degree in quality improvement and patient safety. Dr. Gleicher has extensive experience leading clinical trials in acute postoperative pain, with multiple funded studies and recognized expertise in anesthesia research. He is also a co-developer of the ISAFE technique for adductor canal catheter placement. In his spare time, he enjoys skiing and spending time with his wife and three kids. Dr. dos Santos Fernandes is a specialist in anesthesiology and pain management, trained at University of São Paulo, where he also achieved his PhD and completed a post-doctorate program. He has fellowship training in regional anesthesia and medical education at Mount Sinai Hospital, University of Toronto, and holds multiple certifications, including the superior title in anesthesiology and European diploma in anesthesiology and intensive care. Currently, he is an assistant professor at the University of Toronto and a staff anesthesiologist at Mount Sinai Hospital, with research and clinical focus on regional anesthesia. A retired basketball player and aspiring tennis player, he likes to travel with the family in his free time. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on X @RAPMOnline, LinkedIn @Regional Anesthesia & Pain Medicine, Facebook @Regional Anesthesia & Pain Medicine, and Instagram @RAPM_Online.

Los fármacos para perder peso funcionan.Pero… ¿qué ocurre cuando se dejan? En este episodio analizamos qué dice realmente la evidencia científica sobre la recuperación de peso tras suspender medicamentos como la semaglutida o la tirzepatida.Lo hacemos a partir de un gran estudio publicado en The BMJ y de la editorial que lo acompaña, que ponen el foco en una parte del tratamiento de la obesidad que rara vez se explica.Hablamos de:A qué ritmo se recupera el peso tras dejar estos fármacosQué ocurre con la glucosa, el colesterol y otros marcadores de saludPor qué la recuperación no es un “fracaso personal”, sino una respuesta biológicaEn qué se diferencian los fármacos de los programas basados en hábitosY por qué no pueden considerarse una solución única ni definitivaUn episodio para entender, poner contexto y salir del discurso simplista del antes y después. Sin demonizar los tratamientos, pero sin venderlos como una cura mágica. Porque hablar de salud también es hablar de lo que pasa cuando el tratamiento se acaba.Fuente: https://www.bmj.com/content/392/bmj-2025-085304Editorial: https://www.bmj.com/content/392/bmj.r2586Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.

The class of GLP-1 agonist drugs including Ozempic gained a wide reputation for weight loss in 2025. However, it's well established that weight regain is a common result after people stop their doses. We report on new research which aims to quantify what is happening in the here-and-now for patients who stop using these and similar drugs. Weight regain after cessation of medication for weight management: systematic review and meta-analysis    Also, The BMJ reports on news from Gaza. The Israeli government has issued new directives to strip 37 NGOs of their licences to provide essential aid to the population. This includes Médecins Sans Frontières, the charity directly supporting many of the critically important hospitals in the territory. Gaza is experiencing an especially harsh Winter and MSF warn that this measure could leave Palestinians without lifesaving medical care. Gaza: Israel moves to ban dozens of aid groups in "cynical and calculated" move  Gaza in winter: 29 day old baby dies of hypothermia amid dire conditions   The BMJ's annual appeal is supporting the work of Médecins Sans Frontières (MSF). Around the world, MSF teams are providing maternity care, containing outbreaks, and performing vital surgeries. In areas overwhelmed by conflicts and natural disasters, more lives can be saved when we are in the right place at the right time. Donate today at https://msf.org.uk/bmj-annual-appeal-2025

This episode is available in video form on YouTube: https://youtu.be/1cGrD47eZSk  American science fiction author Kim Stanley Robinson joins Kamran Abbasi to discuss climate disaster, the need for political imagination, and science fiction's vision for health. Kim Stanley Robinson is the acclaimed author of a trilogy of novels, exploring the terraforming and settlement of Mars. His most recent novel, 'Ministry for the Future', was published in 2020. 'Ministry for the Future' sets out a vision for real solutions to our climate crisis, covering global finance, the animal kingdom, rising sea levels, energy production and much more. The book imagines a Ministry that begins its work in 2025. Five years after publication, with 2025 past and gone, The BMJ spoke to Robinson to explore how closely the novel's vision for the future has reflected reality. 01:00 BMJ's New Climate Change Initiative 01:21 Kim Stanley Robinson's Ministry for the Future 04:02 The Role of Political Violence in Climate Action 10:50 The Concept of the Carbon Coin 12:51 The Importance of Global Collaboration 27:32 The Role of Medicine in Climate Change 32:33 Youth and Climate Activism 37:53 Hope and Despair in Climate Action 41:29 Conclusion and Future Works Read more about The BMJ's climate coverage in the latest issue: https://www.bmj.com/content/392/8479

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-466 Overview: Concerns over eating carbohydrate-rich potatoes have been raised over the last decade with numerous studies suggesting worrisome effects on health. Tune in as we unpack findings from a large study that examined the relationship between potato intake and the risk of developing type 2 diabetes mellitus (T2DM), helping you apply evolving nutrition science to patient counseling. Episode resource links: BMJ 2025;390:e082121 http://dx.doi.org/10.1136/bmj-2024‑082121 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-466 Overview: Concerns over eating carbohydrate-rich potatoes have been raised over the last decade with numerous studies suggesting worrisome effects on health. Tune in as we unpack findings from a large study that examined the relationship between potato intake and the risk of developing type 2 diabetes mellitus (T2DM), helping you apply evolving nutrition science to patient counseling. Episode resource links: BMJ 2025;390:e082121 http://dx.doi.org/10.1136/bmj-2024‑082121 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

What really happens when you stop dieting and start eating healthy? In this episode, we hear from two real people who spent years trying to “do the right thing” with food and still felt stuck.  Today, we're joined by Becky and Mark, two ZOE members sharing their personal journeys. Each of them has spent the past two years consistently applying ZOE nutrition principles. Instead of relying on rules or restrictions, they embarked on a science-led journey with ZOE, focused on understanding their bodies. The results? Truly remarkable - ZOE became such an important part of their lives that, alongside 18,000 other members of our community, they became ZOE owners through our crowdfunding. So what changed, and did it last? Alongside Professors Tim Spector and Sarah Berry, we explore how Becky and Mark stay motivated and on track, the lessons they have learned, and the strategies they have used to feel more in control and more confident in their everyday choices. As well as some unexpected shifts along the way. It's a conversation about long-term change, not quick fixes, and you'll leave it with real-life examples of how to make healthy eating a part of your everyday life. If healthy eating wasn't about willpower or perfection, what small change would you start with? And what would help you take that first step this week? Unwrap the truth about your food

Over the holiday season, I'm releasing a couple of previous podcasts that were particularly popular with listeners. This first one is an interview I did with GP Dr David Unwin. David  has been a pioneer in the UK developing and promoting a low-carb approach for treating type 2 diabetes. In 2016, he won the NHS innovator of the year award for his work. His treatment approach has been so successful that  he has put around half his type 2 diabetic patients, who follow a low carb diet, into remission. And as a result, his practice, spends far less on diabetic medication than any of the surrounding GP surgeries. The potential cost savings if this approach was adopted nationally and internationally, would be huge for health services across the world. We tend to think that unless we have a form of diabetes that we don't really need to be concerned about our blood sugar levels, but nothing could be further from the truth. As we get older, all of us unless we change our diet and lifestyle, will see our blood sugar levels rise, this causes our bodies to produce more and more insulin, which can lead to insulin resistance. If we eat a diet high in carbohydrates, this is likely to exacerbate the problem. And that matters because insulin resistance isn't just linked to type 2 diabetes but a wide range of illnesses including high blood pressure, heart disease, Alzheimer's and some cancers too. In the podcast, David discusses the Public Health Collaboration, a charity that he set up with colleagues, which aims to promote metabolic health and so prevent many chronic diseases. Here's a link to it: https://phcuk.org/ And here is a link to David's most recent paper published in BMJ nutrition, also discussed in the podcast: https://nutrition.bmj.com/content/6/1/46   If you would like to support this podcast you can do so via Patreon at or via PayPal. The host of the podcast, Liz Tucker is an award winning medical journalist and former BBC producer and director.  You can follow Liz on Twitter at https://twitter.com/lizctucker and read her Substack newsletter about the podcast at https://liztucker.substack.com Medical Matters with Liz Tucker has been selected by Feedspot as one of the top 15 UK Medical Podcasts https://blog.feedspot.com/uk_medical_podcasts/

It's time for 2025's festive fun! Practicing medicine can be a very visceral experience - and the English language can't always adequately capture the sights, sounds, smells. So Matt Morgan, intensivist and BMJ columnist, is creating medical neologisms, and joins us to share a few. Madhvi Joshi, a GP in London, has written about longevity science, and we hear how the “biohacking” of internet influencers like Bryan Johnson is making its way into the consultation. Navjoyt Ladher and Tim Feeny take us though this year's festive research, and are joined by Anupam Bapu Jena from Harvard, who has been looking at self censorship in the time of Trump, and Melanie de Lange, from the university of Bristol, who has been investigating the impact of daylight savings time. Reading list: A dictionary for medicine's unnamed moments https://www.bmj.com/content/391/bmj.r2476 Science of longevity medicine  https://www.bmj.com/content/391/bmj.r2536  Changes in diversity language in National Institutes of Health grant awards https://www.bmj.com/content/391/bmj-2025-087222  Acute effects of daylight saving time clock changes on mental and physical health in England https://www.bmj.com/content/391/bmj-2025-085962 

What if small changes to how you eat in 2026 could help you feel more energetic, less hungry, and more in control of your health? In this episode, we ask Professor Tim Spector and Professor Sarah Berry a simple question: which everyday food habits make the biggest difference to how we feel? Tim and Sarah outline the eight key principles that inform their approach to eating well and share clear, practical science in a way that's easy to follow. You'll hear simple tips you can try at home, like how to build a balanced breakfast, add more plants to your meals, and choose small habits that are easier to stick to over time. What is one easy change you could try in 2026 to feel a little better? Unwrap the truth about your food

The 2025 year draws to a close with the December episode of RAPM Focus, where RAPM Social Media Editor Alopi Patel, MD, converses with Benjamin S. Brooke, MD, PhD, and Michael “Jay” Buys, MD, following the April 2024 publication of their original research paper, “Postsurgical opioid prescribing among veterans using community care for orthopedic surgery at non-VA hospitals compared to a VA hospital with a transitional pain service: a retrospective cohort study | Regional Anesthesia & Pain Medicine.” The research study looked at opioid prescriptions after orthopedic surgery for veterans, comparing veterans who underwent surgery at the Salt Lake City VA Hospital to those in the community. Dr. Brooke is a Professor of Surgery, Biomedical Informatics (adjunct), Population Health Sciences (adjunct), and Chief of the Division of Vascular Surgery at the University of Utah. He grew up in Salt Lake City, receiving his Doctor of Medicine from the University of Utah before heading east to complete his internship and residency in General Surgery at the Johns Hopkins Hospital. During his surgical residency, Dr. Brooke received his PhD in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. He then completed a fellowship in Vascular Surgery at the Dartmouth-Hitchcock Medical Center. Dr. Buys is an Associate Professor (Clinical) of Anesthesiology at the University of Utah and Chief of the Acute/Transitional Pain Section at the Salt Lake City VA Medical Center. He completed his medical degree at the University of Iowa and residency in anesthesiology at the University of New Mexico, after which he served as an active duty anesthesiologist in the US Air Force at Wilford Hall Medical Center in San Antonio and at Craig Joint Theater Hospital in Afghanistan. *The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice, and it is not intended to function as a substitute for a healthcare practitioner's judgement, patient care, or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others. Podcast and music produced by Dan Langa. Find us on X @RAPMOnline, LinkedIn @Regional Anesthesia & Pain Medicine, Facebook @Regional Anesthesia & Pain Medicine, and Instagram @RAPM_Online.

Depo-Provera was approved in 1992 by U.S. regulators. About 1 in 4 sexually active women in the United States have used the shot at some point, according to the U.S. Centers for Disease Control and Prevention (CDC). Meningiomas are common intracranial tumors with a female predominance. In fact, they are the most common primary brain tumor in women, with an incidence of approximately 12.76 per 100,000 in the general female population. The vast majority of these tumors are benign (World Health Organization [WHO] grade 1) while 15% to 20% of these tumors can behave atypically (WHO grade 2) and rarely, in 1% to 2% of cases, these tumors can be malignant (WHO grade 3). We covered the relationship between Depo-Provera, as a contraceptive agent, and brain meningiomas back in March 2024. With the increase in data, the ACOG released a patient centered counseling tool titled, “Counseling Patients on Birth Control Injection and Meningioma”. The most recent update on this story comes from the FDA, which has granted a medication label change to Depo-Provera (Pfizer) warning of this association. Even though association does not prove causation, the association between depo and meningiomas seems strong (with new data from the US). Does this warning extend to other progestins? Listen in for details. 1. https://podcasts.apple.com/us/podcast/dr-chapas-obgyn-clinical-pearls/id1412385746?i=10006508795722. ACOG's “Counseling Patients on Birth Control Injection and Meningioma” 3. https://www.statnews.com/pharmalot/2025/12/17/fda-pfizer-contraception-cancer-preemption-depoprovera/4. Xiao T, Kumar P, Lobbous M, et al. Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US. JAMA Neurology. 2025;82(11):1094-1102. doi:10.1001/jamaneurol.2025.3011.5. de Dios E, Näslund O, Choudhry M, et al.Prevalence and Symptoms of Incidental Meningiomas: A Population-Based Study.Acta Neurochirurgica. 2025;167(1):98. doi:10.1007/s00701-025-06506-7.6. Schaff LR, Mellinghoff IK.Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329(7):574-587. doi:10.1001/jama.2023.0023.7. BMJ 2024; 384 doi: https://doi.org/10.1136/bmj-2023-078078 (Published 27 March 2024) Cite this as: BMJ 2024;384:e078078

Chegou o episódio escolhido por vocês! Marcela Belleza e Joanne Alves convidam Carol Millon para conversar sobe 6 clinicagens de inibidores de SGLT2, as gliflozinas:Indicações além do DMRisco de CAD euglicêmicaQuando não usar?⁠Cuidados com doença aguda (sick day) e hipovolemia⁠Cuidados pré-operatórioRisco de fratura e amputaçãoReferências:1. Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. Published 2013 Feb 20. doi:10.1186/1741-7015-11-432. Bersoff-Matcha SJ, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019;170(11):764-769. doi:10.7326/M19-00853. Chang HY, et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018;178(9):1190-1198. doi:10.1001/jamainternmed.2018.3034 4. Clar C, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012 Oct 18;2(5):e001007. doi: 10.1136/bmjopen-2012-001007. PMID: 23087012; PMCID: PMC3488745.5. Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583. 6. Fralick M, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. Published 2020 Aug 25. doi:10.1136/bmj.m28127. Li D, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-355. doi:10.1111/dom.128258. Neal B, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.e11. doi:10.1016/j.ahj.2013.05.0079. Nyirjesy P, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-1178. doi:10.1185/03007995.2012.69705310. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa181174411. Rosenwasser RF, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. PMID: 24348059; PMCID: PMC3848644.12. Sridharan K, Sivaramakrishnan G. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. Expert Opin Drug Saf. 2025;24(7):797-804. doi:10.1080/14740338.2024.237775513. Ueda P,  et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. Published 2018 Nov 14. doi:10.1136/bmj.k436514. Watts NB, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18. PMID: 26580237; PMCID: PMC4701850.15. Zhuo M, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.3076216. Emerson Cestari Marino, Leandra Anália Freitas Negretto, Rogério Silicani Ribeiro, Denise Momesso, Alina Coutinho Rodrigues Feitosa, Marcos Tadashi Kakitani Toyoshima, Joaquim Custódio da Silva Junior, Sérgio Vencio, Marcio Weissheimer Lauria, João Roberto de Sá, Domingos A. Malerbi, Fernando Valente, Silmara A. O. Leite, Danillo Ewerton Oliveira Amaral, Gabriel Magalhães Nunes Guimarães, Plínio da Cunha Leal, Maristela Bueno Lopes, Luiz Carlos Bastos Salles, Liana Maria Torres de Araújo Azi, Amanda Gomes Fonseca, Lorena Ibiapina M. Carvalho, Francília Faloni Coelho, Bruno Halpern, Cynthia M. Valerio, Fabio R. Trujilho,  Antonio Carlos Aguiar Brandão, Ruy Lyra e Marcello Bertoluci. Rastreamento e Controle da Hiperglicemia no Perioperatório – Posicionamento Conjunto da Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO). Diretriz Oficial da Sociedade Brasileira de Diabetes (2025). DOI: 10.29327/5660187.2025-10 , ISBN: 978-65-5941-367-6.17. Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2024;47(6):933-940. doi:10.2337/dc23-112918. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022;28(9):884-888. doi:10.1016/j.eprac.2022.06.00619. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis. JAMA Netw Open. 2024;7(3):e242744. Published 2024 Mar 4. doi:10.1001/jamanetworkopen.2024.274420. Fleming N, Hamblin PS, Story D, Ekinci EI. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Endocrinol Metab. 2020;105(8):dgaa200. doi:10.1210/clinem/dgaa20021. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-622. Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024-2034. doi:10.1056/NEJMra211501123. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa150472024. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa161192525. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa181238926. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa191130327. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa202219028. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa210703829. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa202481630. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in...

Babies exposed to less sugar during pregnancy and early childhood have dramatically lower risks of heart disease, stroke, and diabetes later in life, showing that the first 1,000 days shape lifelong cardiovascular health A large BMJ study found that those born under postwar sugar rationing had up to 31% lower risk of stroke and 27% lower risk of dying from heart disease, with the strongest benefits seen when sugar restriction lasted through infancy Early sugar restriction helps prevent fetal hyperglycemia and inflammation that damage developing blood vessels, leading to stronger heart function, smoother blood flow, and better blood pressure regulation in adulthood Most U.S. infant formulas contain added sugars equal to about two cans of soda per day for a formula-fed baby, yet labels don't disclose these ingredients — leaving parents unaware of the hidden metabolic risks Parents can safeguard their child's heart and metabolism by breastfeeding or making homemade formula, delaying all added sugars for the first two years, and modeling healthy eating habits at home

You've read about how this groundbreaking trial on ketamine vs etomidate for RSI "Changes Everything!" on the socials. Or perhaps "it's horribly biased and unnecessary... we're already knew all this!". Why? Well.. social media. Listen in as Dr Jarvis discusses not just this trial, but what the evidence landscape was before it was released. Why was it done, how was it done, what does it show, and how can we integrate it into our practice?Citations:1. Casey JD, Seitz KP, Driver BE, et al. Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults. N Engl J Med. Published online December 9, 2025.2. Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet. 2009;374(9686):293-300. 3. Matchett G, Gasanova I, Riccio CA, et al. Etomidate versus ketamine for emergency endotracheal intubation: a randomized clinical trial. Intensive Care Med. 2022;48(1):78-91. 4. Koroki T, Kotani Y, Yaguchi T, et al. Ketamine versus etomidate as an induction agent for tracheal intubation in critically ill adults: a Bayesian meta-analysis. Crit Care. 2024;28(1):48. 5. Yeh RW, Valsdottir LR, Yeh MW, et al. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ. 2018;363:k5094. doi:10.1136/bmj.k5094

In this deeply vulnerable solo episode, Darin dismantles one of the great myths of modern self-help: that transformation is something you're meant to "do alone." Drawing from neuroscience, anthropology, physiology, and personal experience, he reveals the biological truth — the human nervous system is designed to heal, grow, and stabilize in relationship, not isolation. This conversation explores why loneliness creates physiological damage, why belonging is a survival requirement (not a luxury), and how to intentionally rebuild the village your cells have been waiting for. If you've ever felt like you're doing all the "inner work" but still feel disconnected, this episode is the medicine.     What You'll Learn in This Episode 00:00:00 - Opening SuperLife intro narration. 00:00:32 - Sponsor: Therasage — family-driven healing technology, infrared and natural frequency support, details on discount. 00:02:11 - Darin begins the episode — "You were never meant to do this alone." 00:02:22 - The forgotten biology of community and why humans are not built for isolation. 00:03:01 - Your nervous system regulates in relationship — the vagus nerve, safety, co-regulation. 00:03:19 - Social engagement system — coherence, cortisol regulation, belonging as biology. 00:04:03 - Social pain = physical pain; the Baumeister research; the architecture of human connection. 00:05:01 - Tribes, proximity, shared life — Dunbar's number and the limits of real human networks. 00:05:30 - Loneliness as physiology — cortisol elevation, inflammation, disrupted sleep, gray-matter changes. 00:07:01 - Personal growth was never meant to be personal — autonomy, competence, relatedness, love. 00:07:55 - If nobody sees you, your nervous system can't relax — mirrors vs willpower. 00:08:31 - Social contagion of behavior — your network shapes your health. 00:09:01 - Who are you wired into? Environment as epigenetic instruction. 00:10:12 - Why online spaces generate stress instead of transformation. 00:10:35 - Darin's vision: community as a practice, not performance. 00:11:29 - Sponsor: Bite Toothpaste — plastic waste, sustainability, clean ingredients, discount code. 00:13:11 - What if growth wasn't a grind? What if healing was tribal again? 00:13:35 - Building intentional space — not fandom, not following, but practice. 00:14:11 - Supporting the nervous system through community; truth over scrolling. 00:15:04 - Why Patreon — structure, privacy, belonging, circle not feed. 00:15:23 - People looking for truth, depth, real connection — not performance. 00:15:51 - Start building your circle; align with those who align with you. 00:16:12 - You need to be seen, not fixed — community as transformation. 00:17:00 - One person can change your life — the power of being mirrored. 00:17:31 - Men's group, friendships, working out — the daily relational fabric. 00:18:01 - If you're lonely or disconnected, the desire for connection already shifts your biology. 00:18:41 - Darin reflects on a hard year, pain, stem cells, and the deeper healing found in being witnessed. 00:19:26 - Every cell responds when you say yes to deeper connection — the universe moves with it. 00:20:07 - Understanding human biology: we want love, connection, safety, belonging. 00:20:36 - Cutting through "what do you eat" questions — the real priority is connection. 00:21:00 - Closing: "Joy and happiness. Connection. We are built for it… I love you."     Thank You to Our Sponsors Therasage: Go to www.therasage.com and use code DARIN at checkout for 15% off Bite Toothpaste: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order.     Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only  $7.49/month at https://patreon.com/darinolien     Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences     Key Takeaway "You don't need to be fixed. You don't need to be saved. You just need to be seen — and we cannot do that alone."     Bibliography Neuroscience & Biology of Connection Porges, S. W. (2011). The Polyvagal Theory: Neurophysiological Foundations of Emotions, Attachment, Communication, and Self-Regulation. New York: W.W. Norton. Link to Book Information (Norton) Lieberman, M. D. (2013). Social: Why Our Brains Are Wired to Connect. New York: Crown Publishers. Link to Book Information (Penguin Random House) Eisenberger, N. I. (2012). "The pain of social disconnection: examining the shared neural underpinnings of physical and social pain." Nature Reviews Neuroscience, 13(6), 421–434. Link to Study (PubMed) Thayer, J. F. & Lane, R. D. (2000). "A model of neurovisceral integration in emotion regulation and dysregulation." Journal of Affective Disorders, 61(3), 201–216. Link to Study (ScienceDirect) Psychology of Belonging & Motivation Baumeister, R. F. & Leary, M. R. (1995). "The need to belong: desire for interpersonal attachments as a fundamental human motivation." Psychological Bulletin, 117(3), 497–529. Link to Study (PubMed) Deci, E. L. & Ryan, R. M. (2000). "The 'what' and 'why' of goal pursuits: Human needs and the self-determination of behavior." Psychological Inquiry, 11(4), 227-268. Link to Study (SelfDeterminationTheory.org) Adler, A. (1930s). What Life Could Mean to You. Link to Book Information (Google Books) (Note: Various editions exist) Social Networks & Behavioral Contagion Christakis, N. A. & Fowler, J. H. (2007). "The spread of obesity in a large social network over 32 years." New England Journal of Medicine, 357, 370-379. Link to Study (NEJM) Fowler, J. H. & Christakis, N. A. (2008). "Dynamic spread of happiness in a large social network." BMJ, 337, a2338. Link to Study (BMJ) Centola, D. (2018). How Behavior Spreads: The Science of Complex Contagions. Princeton University Press. Link to Book Information (Princeton University Press) Anthropology & Human Ecology Dunbar, R. I. M. (1992). "Neocortex size as a constraint on group size in primates." Journal of Human Evolution, 22(6), 469-493. Link to Study (ScienceDirect) Henrich, J. (2016). The Secret of Our Success: How Culture Is Driving Human Evolution, Domesticating Our Species, and Making Us Smarter. Princeton University Press. Link to Book Information (Princeton University Press) Loneliness, Inflammation & Health Outcomes Holt-Lunstad, J. et al. (2010). "Social relationships and mortality risk: a meta-analytic review." PLoS Medicine, 7(7), e1000316. Link to Study (PLoS Medicine) Cacioppo, J. T. & Cacioppo, S. (2014). "Social relationships and health: The toxic effects of perceived social isolation." Social and Personality Psychology Compass, 8(2), 58-72. Link to Study (PubMed) Cole, S. W. (2014). "Human social genomics." PLoS Genetics (Cited as PLoS Biology in text, corrected to Genetics based on search), 10(8), e1004601. Link to Study (PLoS Genetics) Group Rituals, Synchrony & Physiology Tarr, B., Launay, J., & Dunbar, R. (2014). "Music and social bonding: 'self-other' merging and neurohormonal effects." Frontiers in Psychology, 5, 1096. Link to Study (Frontiers) Konvalinka, I. et al. (2011). "Synchronized arousal between performers and related spectators in a fire-walking ritual." Proceedings of the National Academy of Sciences, 108(20), 8514–8519. Link to Study (PNAS) Digital Communities & Social Learning Lave, J. & Wenger, E. (1991). Situated Learning: Legitimate Peripheral Participation. Cambridge University Press. Link to Book Information (Cambridge University Press) Wenger, E. (1998). Communities of Practice: Learning, Meaning, and Identity. Cambridge University Press. Link to Book Information (Cambridge University Press)  

Welcome to Pulse: Hot Topics, where Louise and George unpack the big shifts shaping healthcare right now - from billion-dollar hype to human-level trust.Are AI Scribes The Billion-Dollar Burnout Band-Aid?Doctors adore them, investors can't stop funding them - We dig into the paradox of technology that makes clinicians happy but might not be improving productivity—and why transparency is becoming urgent as these tools expand into agentic workflows.Chatbots in Therapy: When AI Joins the SessionFrom therapists secretly using ChatGPT mid-session, to patients uploading their medical records for advice, and one founder shutting down his AI therapy app over safety fears — can AI-mediated care ever truly be therapeutic?New Zealand's Digital Déjà VuAfter a tough 2024, New Zealand's back with a 10-year digital health plan, a new Centre for Modernisation, and a promise of one innovation a month. But with no funding announcement and an election looming, is this genuine commitment or just another round of hopeful planning? Tender watch is on.MIT's Top 10 Breakthrough TechnologiesMIT Technology Review's annual list has brain–computer interfaces voted readers' #11 pick. Are BCIs about to finally enter their translation era? And would George drill a hole in his head for the tech?The BMJ vs. TikTok MedicineWhat happens when money, marketing, medicine, and misinformation collide? Raffael Heiss can tell you as he's mapped it. Spoiler alert: it's not god. Tina Purnat argues we can't regulate this away—we need to recognise the information environment as a determinant of health.Resources:AI Scribes paper, NEJM AI LinkNZ DH Strategy, Pulse+IT Story LinkMIT Technology Review's Breakthrough Tech List LinkPublic health challenges of ‘medical influencers' BMJ LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

In part one of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss the process of diagnosing FND.  Show citation:  Aybek S, Perez DL. Diagnosis and management of functional neurological disorder. BMJ. 2022;376:o64. Published 2022 Jan 24. doi:10.1136/bmj.o64 

There is an enormous amount of research on treatment for ADHD - pharmaceutical and otherwise. But not all of those trials, or meta-analyses, are of high quality; and not many compare the whole literature.  Now a new umbrella review - a review of reviews - tries to give a broad overview of the whole evidence base. Corentin Gosling, associate professor at the Université Paris Nanterre, joins us to set out the benefits and harms of ADHD therapies.   Also, the BMJ's been investigating the employment of doctors on “local” contracts in the NHS - and our latest look at this exposes what some have described as a “gig economy”, with doctors plugging rota gaps but missing out on training, development, and salary progression. Rebecca Coombes, head of journalism at The BMJ explains more.   Finally, Tom Frieden is former head of the US Centers for Disease Control, and current CEO of Resolve to Save Lives - he's written a new book on public health. He joins us to talk about what actually improves health at a population level, and why the current US administration's approach to staffing the CDC is leaving the country open to danger.   Reading list Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making Revealed: Thousands of NHS doctors are trapped in insecure “gig economy” contracts  

Lorsque l'on parle de « brûler » des graisses, l'image qui nous vient souvent en tête est celle d'un glaçon qui fond. En réalité, la biologie raconte une histoire bien plus surprenante : lorsque nous perdons de la graisse après un effort physique, la majorité de cette graisse quitte notre corps… par la respiration.Tout commence dans nos cellules. Lorsqu'elles ont besoin d'énergie — pendant une séance de sport, une marche rapide ou même une simple montée d'escaliers — elles vont puiser dans leurs réserves : les triglycérides. Ces molécules sont stockées dans les adipocytes, nos cellules graisseuses. Leur rôle est d'emmagasiner de l'énergie sous une forme compacte et stable, en attendant un moment de besoin. Quand l'organisme réclame du carburant, ces triglycérides sont démontés en acides gras et en glycérol.C'est dans les mitochondries que la véritable « combustion » a lieu. Grâce à l'oxygène que nous respirons, ces acides gras sont métabolisés. Et c'est là que survient la révélation : la graisse ne disparaît pas, elle se transforme. Son produit final n'est pas de la chaleur ni de la sueur, mais principalement du dioxyde de carbone (CO₂) et de l'eau.Pour donner une idée concrète : si vous perdez 100 g de graisse, environ 84 g seront transformés en CO₂. À un rythme respiratoire normal, cela représente plusieurs dizaines de litres de CO₂ expirés au fil des heures. La dépense énergétique d'une séance de sport d'intensité modérée peut mobiliser 50 à 150 g de graisse, ce qui signifie que l'on expire littéralement des dizaines de grammes de graisse sous forme de CO₂ après un seul entraînement.Les 16 % restants de la masse initiale sont transformés en eau, éliminée par la sueur, l'urine et même la vapeur d'eau expirée. Contrairement aux idées reçues, la transpiration n'est pas la preuve que nous « brûlons » de la graisse : elle sert surtout à refroidir le corps.Cette découverte — popularisée après une étude publiée en 2014 dans BMJ — a renversé nombre d'idées que l'on croyait acquises : maigrir est avant tout un processus respiratoire. Chaque mouvement accélère la transformation des triglycérides en CO₂, et c'est en expirant que nous perdons réellement du poids.En résumé : pour perdre de la graisse, il faut bouger… et respirer. L'oxygène que nous inspirons, et surtout le CO₂ que nous expirons, portent la signature chimique de notre perte de poids. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

This week primary care physicians Gary, Henry, Kate and Mark discuss the safety of CBD, a new guideline for managing adults with hypertension, whether COVID-19 vaccines are still effective, and a living guideline from the BMJ to help us choose the best diabetes drugs. Links to stuffEssential Evidence Plus Illinois Academy of Family Physicians meeting Dec 6 in Naperville, IL (Kate, Gary and Mark)   North Dakota Academy of Family Physicians Big Sky Conference Jan 19 in Big Sky, Montana (Gary and Kate) Safety of CBDACC/AHA Hypertension guidelinePREVENT-CVD risk calculatorEfficacy of COVID-19 vaccinesBMJ living guideline for diabetesBMJ MATCH-IT interactive tool for selecting drugs

This Week on the Pod: Rain, Parades, Hive Minds, and… Ben's Brain for Rent? This week's episode opens with a very rainy round of real-life updates. Ben has been slammed with work and declares—formally, officially, irrevocably—that poetry is better than parades. (He is fully prepared to defend this position.) Meanwhile, Steven reports that the local parade and festival still happened despite the rain, because sometimes community spirit just refuses to check the weather. And Devon? He keeps forgetting that he's technically a Texan now, which raises several questions about residency, identity, and barbecue obligations. But the week wasn't all jokes—Ben also shared the sad news that Orion has passed. He was a very good boy, and the pod raises a collective toast. Ben's been spending time catching up on life, trying to relearn what "rest" even means, and also casually dropping the bomb that Affinity is now free. (Yes, really—go see for yourself at affinity.studio.) And while you're browsing, you can apparently rent Ben's actual mind at Penciledin.com, which sounds like a threat but is, in fact, a service. Steven also let us know that the Fallout Season 2 trailer is out, so it's time to emotionally prepare for more post-apocalyptic chaos.  Future or Now: Tylenol, Autism, and the Psychology of Hive Minds Devon kicks off this segment with actual real science: new research shows no clear link between acetaminophen (Tylenol) and autism, which is a big deal considering how long that concern has been floating around. (Links to ScienceDaily and the BMJ included in the show notes for the skeptics and science nerds.) Then we collectively decide: yes, we need to talk about Plur1bus. And we go deep. This is a full-spoiler discussion, so skip ahead if you're still watching. We cover everything—from the protagonist who's also the antagonist, to the messy moral math of a hive mind, to Devon's incredibly passionate speech about wanting to understand hive-mind psychology. Steven brings up that Internet-as-proto-hivemind theory, and Ben drops several very good points as per tradition. If you want episode breakdowns, the Wikipedia page has everything laid out neatly and also serves as a reminder that this show is way smarter than any of us expected when we hit "play." Book Club (Sort Of) We skipped Book Club this week because there was simply too much Plur1bus to process. Next week: We're reading City Grown From Seed by Diana Dima. Content warning: domestic violence / domestic abuse. You can read it for free on Strange Horizons.

It's the BMJ's annual climate issue - and in this episode, we'll be hearing about more ways in which climate mitigation is good for health.   Firstly, climate change is fuelling conflict, and exacerbating the impact it has on fragile healthcare systems. Andy Haines, from the London School of Hygiene and Tropical Medicine, and Barbora Sedova, from Potsdam Institute for Climate Impact Research, discuss how climate and conflict intersect, and what they think needs to be done to combat it.   “Car spreading”, the recent tendency for cars to become bigger and heavier is not only harming the climate, but it's also harming pedestrians.  Anthony Laverty, associate professor of public health at Imperial College London, and trauma surgeon Cleo Kenington explain why SUVs are more lethal in accidents, and why France is bucking the trend in sales.   Finally, Jocalyn Clark, the BMJ's international editor joins us to talk about women's health innovation and why tech bros aren't the people to be leading it.   Reading list:   The climate issue: Brazil and the climate crisis   Tackling the complex links between climate change, conflict, and health   Reducing the harms from ever larger cars   Transforming women's health through innovation

The ARRIVE Trial and the Term Breech Trial reshaped modern birth practices in ways researchers never intended. From skyrocketing inductions to the loss of vaginal breech training, these studies reveal how even “gold-standard” science can miss the human side of birth.Clara invites you to take a mindful pause: to look beyond the data, question how evidence gets translated into policy, get curious about how the research was designed, and remember that true evidence-based care must center the individual—not just the research.You'll Learn:What the ARRIVE Trial and the Term Breech Trial actually found (and what they didn't)How these studies shifted policy, practice, and training worldwideWhy over-reliance on “evidence” can erase skills, intuition, and personal choiceHow to bring mindfulness into your decision-making about induction, breech birth, or any medical recommendationWhy traditional and holistic birth practices still matter—even if they've never been studiedMindful Reflection“Mindfulness isn't about ignoring evidence—it's about pausing long enough to ask, ‘Does this research apply to me, in my body, in this context?' True evidence-based care is a dialogue between research, clinician experience, and your own wisdom.”Resources MentionedDownload Clara's Free Birth Plan Template, used at over 5,000 births.Ready for an evidence based birth class? Check out A Path to A Powerful BirthThe Birth Advocacy Toolkit is a great option for expectant parents who have already taken a class but want to make sure their preferences are heard and want evidence based information to help make their decisions. Evidence Based Birth: Evidence on the ARRIVE Trial and Elective Induction at 39 WeeksEvidence Based Birth: Evidence on Breech BirthGrobman WA, et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. NEJM, 2018.Evidence Based Birth: “Evidence on the ARRIVE Trial and Elective Induction at 39 Weeks.”Nethery E, et al. Obstet Gynecol, 2023. Post-ARRIVE induction impact study.Hannah ME, et al. Planned Cesarean vs Planned Vaginal Birth for Breech. Lancet, 2000.Kotaska A. BMJ, 2004. “Inappropriateness of RCTs for complex intrapartum phenomena.”Goffinet F, et al. PREMODA Study. Am J Obstet Gynecol, 2006.RCOG Green-top Guideline No. 20b (2017).ACOG Committee Opinion No. 745 (2018).SOGC No. 384 (2019).Get 20% off your first monthly subscription with NEEDED Vitamins 

Do you routinely order prophylactic antibiotics at time ofsecond-degree laceration repair? Is there data for that? While the use of prophylacticantibiotics “is reasonable” (per ACOG PB 198) for OASIS lacerations, what doesthe data look like for second degree lacs? Well, the answer is both supportiveAND non-supportive of that practice! In this episode, we will cover a brand newpublication (RCT) from BMJ on this very issue, and also highlight a meta-analysisfrom Plos One (May 2025) that also examined this question. Listen in fordetails!1.     ACOG PB 1982.     Armstrong H, Whitehurst J, Morris RK, HodgettsMorton V, Man R; CHAPTER group. Antibiotic prophylaxis for childbirth-relatedperineal trauma: A systematic review and meta-analysis. PLoS One. 2025 May9;20(5):e0323267. doi: 10.1371/journal.pone.0323267. PMID: 40344566; PMCID:PMC12064200.3.     Risk of infection and wound dehiscence after useof prophylactic antibiotics in episiotomy or second degree tear (REPAIR study):single centre, double blind, placebo controlled randomised trial. BMJ 2025; 391doi: https://doi.org/10.1136/bmj-2025-084312 (Published 29 October 2025): BMJ2025;391:e084312

Featuring an interview with Dr Aaron Lisberg, including the following topics: Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) for Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): A Pooled Analysis of the TROPION-Lung01 and TROPION-Lung05 Trials (0:00) Ahn M-J et al. Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05. ESMO Asia 2024;Abstract LBA7 Ahn M-J et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol 2025;[Online ahead of print]. Abstract Sacituzumab Tirumotecan for Previously Treated Advanced EGFR-Mutated NSCLC: Results from the Randomized OptiTROP-Lung03 Study (7:08) Fang W et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: Multicentre, open label, randomised controlled trial. BMJ 2025;389:e085680. Abstract Zhang L et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. ASCO 2025;Abstract 8507. Combination of Dato-DXd and Immunotherapy as First-Line Therapy for Patients with Advanced NSCLC (13:12) Cuppens K et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4). ESMO Targeted Anticancer Therapies Congress 2025;Abstract 8O. Okamoto I et al. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol 2024;20(37):2927-36. Abstract Levy BP et al. TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol 2023;19(21):1461-72. Abstract Aggarwal C et al. AVANZAR: Phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as 1L treatment of advanced/mNSCLC. World Conference on Lung Cancer (WCLC) 2023;Abstract P2.04-02. TROP2-Targeting Antibody-Drug Conjugates as Neoadjuvant and/or Adjuvant Therapy for Patients with Resectable NSCLC (19:08) A phase III, randomised, open-label, global study of adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care, following complete tumour resection, in participants with Stage I adenocarcinoma non-small cell lung cancer who are ctDNA-positive or have high-risk pathological features (TROPION-Lung12). NCT06564844 Cascone T et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: The platform phase 2 NeoCOAST-2 trial. Nat Med 2025;31(8):2788-96. Abstract CME information and select publications

In this solo episode, Darin pulls back the curtain on one of the most important parts of his life:  he prepares for travel. From the supplements that keep his immune system strong to hydration hacks, adaptogenic elixirs, and EMF protection, this episode is a masterclass in staying grounded and resilient on the road. Travel doesn't have to destroy your health — it can actually elevate it. With a few intentional rituals, smart packing, and awareness, you can turn every trip into an opportunity to deepen your energy, focus, and connection to yourself. What You'll Learn 00:00:00 – Why travel is stressful and how to transform it into an empowering, health-boosting experience 00:01:00 – Darin's supplement protocol: Vitamin D3/K2, probiotics, zinc, vitamin C, and glutathione for immune defense 00:03:00 – The antioxidant power of glutathione and why it's critical for long flights and radiation exposure 00:04:30 – How CBD and terpenes support stress resilience and circadian rhythm through the endocannabinoid system 00:05:20 – Why magnesium and NAD are the unsung heroes of travel recovery and energy 00:06:30 – Darin's morning elixir recipe: cacao, guarana, ashwagandha, chaga, ginseng, and monk fruit 00:08:00 – Hydration 101: how to use a manual RO filter, mineralize your water, and ditch plastic 00:10:00 – How to build nutrient density into travel days using chlorella, spirulina, Shakeology, and Barukas 00:12:00 – Travel nutrition sovereignty: packing your own snacks, fasting, and avoiding airline food 00:14:00 – Movement anywhere: Darin's “portable gym” using bungee cords and bodyweight routines 00:16:00 – The 3-hour morning ritual: NewCalm, Healing Codes, journaling, cacao, red light therapy, and breathwork 00:20:00 – How to avoid radiation scanners, mitigate EMFs, and use WaveGuard for energy field protection 00:22:00 – Why Darin microdoses nicotine for cognitive focus and immune modulation 00:23:00 – Breathing practices for immune strength: 3–4 rounds of 40 deep breaths, Wim Hof style 00:24:00 – How to pack fruit and salads in mason jars to stay hydrated and nourished on planes 00:26:00 – Grounding after flights: barefoot on the earth, morning sunlight, and re-aligning your circadian rhythm Thank You to Our Sponsors Manna Vitality: Go to mannavitality.com/ or use code DARIN20 for 20% off your order. Fatty15: Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DARIN and using code DARIN at checkout. Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences Key Takeaway “Preparation is sovereignty. When you take responsibility for your nutrition, your hydration, and your energy before you travel, you're no longer surviving the trip — you're expanding through it.” Bibliography Martineau AR et al. Vitamin D supplementation to prevent acute respiratory infections: systematic review. BMJ. 2017. Goldenberg JZ et al. Probiotics for prevention of respiratory infections. Cochrane Database. 2017. Hemilä H. Vitamin C and zinc in common cold. Nutrients. 2017. Blessing EM et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015. Morris HJ et al. Spirulina and chlorella as functional foods. Nutrients. 2022. Longo VD, Panda S. Fasting, circadian rhythms, and time-restricted feeding. Cell Metabolism. 2016. Booth FW et al. Waging war on physical inactivity. J Physiol. 2017. Balmori A. Electromagnetic pollution from radiofrequency fields. Pathophysiology. 2015. Kox M et al. Voluntary activation of sympathetic nervous system and attenuation of the innate immune response. PNAS. 2014.

For several decades, saturated fat was wrongly blamed for heart disease, while vegetable oils quietly caused a surge in obesity, inflammation, and chronic metabolic disorders Newly appointed FDA commissioner Dr. Marty Makary is now leading efforts to revise outdated dietary guidelines that were built on cherry-picked data from Ancel Keys' Seven Countries Study A 2016 BMJ-published reanalysis found replacing saturated fat with linoleic acid-rich vegetable oils increased cardiovascular deaths, despite lowering cholesterol Investigative journalist Dr. Maryanne Demasi faced vicious backlash after exposing the flawed science behind saturated fat demonization in her documentary “Heart of the Matter” Industrial seed oils like canola and soybean are now linked to mitochondrial damage, inflammation, and chronic illness — while saturated fat is finally being recognized as metabolically supportive

This week, we're unpacking the big stories shaping food, health and how we live. We start with a major BMJ study showing that eating chips three times a week raises type 2 diabetes risk by 20% but baked or boiled potatoes don't carry the same danger. We'll share why the way you cook them matters, plus the genuine health benefits of potatoes when they're not fried. Next, a Guardian feature on “otroverts” — people who don't feel at home in groups but aren't introverts either. Psychiatrist Dr Rami Kaminski explains why this isn't a deficit, how it can be a strength, and what it tells us about solitude, loneliness and connection. And from the Times, the science of the “holiday brain-boost.” We explore how holidays can slow cognitive ageing, why even short breaks matter, and the habits from naps to mindfulness and movement that help the benefits last for weeks after you're home. Plus, the trends: Australia's world-first ban on social media for under 16s, and the UK government's plan to restrict energy drink sales to teenagers. Alongside all that, Ella shares her first weekend in the new house, picking homegrown fruit and veg and welcoming two new puppies, plus a listener story that reveals just how many ultra processed additives can be hiding in a single mini cupcake. Catch Rhi discussing UPFs and The Unprocessed Plate at Waterstones - London Gower Street and Chroleywood Library Learn more about your ad choices. Visit podcastchoices.com/adchoices

From The Simpsons' Big Book of British Smiles to Austin Powers' ochre-tinged grin, American culture can't stop bad-mouthing English teeth. But why? Are they worse than any other nation's? June Thomas drills down into the origins of the stereotype, and discovers that the different approaches to dentistry on each side of the Atlantic have a lot to say about our national values. In this episode, you'll hear from historians Mimi Goodall, Mathew Thomson, and Alyssa Picard, author of Making the American Mouth; and from professor of dental public health Richard Watt. This episode was written by June Thomas and edited and produced by Evan Chung, Decoder Ring's supervising producer. Our show is also produced by Willa Paskin, Katie Shepherd, and Max Freedman. Merritt Jacob is Senior Technical Director. If you have any cultural mysteries you want us to decode, email us at DecoderRing@slate.com or leave a message on our hotline at (347) 460-7281. Sources for This Episode Goodall, Mimi. “Sugar in the British Atlantic World, 1650-1720,” DPhil dissertation, Oxford University, 2022. Mintz, Sidney. Sweetness and Power: The Place of Sugar in Modern History, Penguin Books, 1986. Picard, Alyssa. Making the American Mouth: Dentists and Public Health in the Twentieth Century, Rutgers University Press, 2009.  Thomson, Mathew. “Teeth and National Identity,” People's History of the NHS. Trumble, Angus. A Brief History of the Smile, Basic Books, 2004. Wynbrandt, James. The Excruciating History of Dentistry: Toothsome Tales & Oral Oddities from Babylon to Braces, St. Martin's Griffin, 2000. Watt, Richard, et al. “Austin Powers bites back: a cross sectional comparison of US and English national oral health surveys,” BMJ, Dec. 16, 2015. Get more of Decoder Ring with Slate Plus! Join for exclusive bonus episodes of Decoder Ring and ad-free listening on all your favorite Slate podcasts. Subscribe from the Decoder Ring show page on Apple Podcasts or Spotify. Or, visit slate.com/decoderplus for access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices